RTP Mobile Logo
Visiting Professors: Breast Cancer Edition, Issue 1, 2011
Released August 2011

Featuring Dr Harold J Burstein’s perspective on a day spent visiting patients with breast cancer in the clinic of community oncologist Dr Richard S Zelkowitz. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Individualized treatment decisions for patients with early, locally advanced or metastatic breast cancer are driven by disease- and patient-specific characteristics. The numerous therapeutic agents and regimens with significant activity in the management of breast cancer provide ample opportunity to deliver tailored care. However, the multiplicity of alternatives may also yield clinical scenarios in which several acceptable treatment options are available, with the optimal strategy being highly debatable and dependent on a thorough understanding of each agent’s unique benefits and risks.

    To provide clinicians with therapeutic strategies to address the disparate needs of patients with breast cancer, the Visiting Professors audio series employs an innovative case-based approach that unites the perspectives of leading breast cancer investigators and community oncologists as they explore the intricacies of making treatment decisions. Upon completion of this CME activity, medical oncologists should be able to formulate an up-to-date and more complete approach to the care of patients with breast cancer.

    LEARNING OBJECTIVES

    • Apply case-based learning, innovative communication strategies and shared clinical insight to provide comprehensive and compassionate oncology care.
    • Use currently available tissue-based genomic assays to assist with therapeutic decision-making in the management of node-negative and node-positive early breast cancer.
    • Construct an evidence-based treatment algorithm integrating anti-HER2 therapies for the treatment of HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings.
    • Effectively integrate biologic, hormonal and cytotoxic therapy into the multifaceted management of metastatic breast cancer.
    • Apply the results of emerging research to effectively and safely integrate bevacizumab into the first- and second-line treatment of HER2-negative metastatic breast cancer.
    • Counsel appropriately selected patients about the availability of ongoing clinical trial participation.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY Dr Burstein had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr ZelkowitzSpeakers Bureau: Genomic Health Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech BioOncology and Genomic Health Inc.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2011
    Expiration date: August 2012

     

Acknowledge and close

Listen to audio:
Visiting Professors: Breast Cancer Edition, Issue 1, 2011
Released August 2011

Featuring Dr Harold J Burstein’s perspective on a day spent visiting patients with breast cancer in the clinic of community oncologist Dr Richard S Zelkowitz. (Audio Content)

Read print: